Endo International plc is an Irish-domiciled generics and specialty branded pharmaceutical company that generated over $3 billion in revenue in 2019. Endo develops, manufactures, and distributes pharmaceutical products and medical devices worldwide. The company's products include pain management medications, testosterone replacement therapies, and surgical products. Endo has faced legal challenges related to its marketing practices and the safety of its products, including a $10 million settlement with the state of New York over its marketing of opioid painkillers. In 2020, Endo announced that it would be divesting its portfolio of branded pharmaceuticals to focus on its generics business.